AbelZeta Pharma, Inc. Establishes Scientific Advisory Board to Propel Advancements in Inflammatory and Immunological Diseases
AbelZeta Pharma, Inc., a global clinical-stage biopharmaceutical company specializing in the discovery and development of innovative cell-based therapeutic products, has officially formed a Scientific Advisory Board (SAB) to drive progress in its cell therapies for treating inflammatory and immunological diseases. The SAB comprises four distinguished scientists from the United States and Europe.
Tony (Bizuo) Liu, Chairman, and CEO of AbelZeta expressed enthusiasm about the formation of the SAB, stating, “The SAB will help us to gain useful knowledge about the latest treatment options, as well as disease pathology and potential biomarkers. We work on many inflammatory and immunological diseases that will allow us to gain strategic insights and speed up the clinical development of these assets.”
The four industry experts joining the SAB are:
Peter Lipsky, M.D.: Former Chair of the Medical and Scientific Committee of the Arthritis Foundation, Director of the Intramural Research Program, and chair of the Autoimmunity Branch at the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health. Dr. Lipsky is the founder and CEO of AMPEL BioSolutions.
Mary Crow, M.D.: Physician-in-Chief Emeritus at Hospital for Special Surgery in New York, Professor of Medicine at Weill Cornell Medical College, and Professor of Immunology in its Graduate School of Medical Sciences.
Maria Dall’Era, M.D.: Jean S. Engleman Distinguished Professor and Chief of the Division of Rheumatology at the University of California, San Francisco (UCSF).
Thomas Dörner, M.D.: Professor of Rheumatology and Clinical Immunology for Innovative Therapies for Autoimmune Diseases at Charité University Hospitals, Berlin.
The SAB will play a crucial role in providing insights into the latest treatment options, disease pathology, and potential biomarkers to accelerate the clinical development of AbelZeta’s cell-based therapeutic products. The focus of the company’s autoimmune CAR-T program includes CD20/BCMA and BCMA/CD19 bispecific CAR constructs, targeting both B cells and plasma cells.
AbelZeta aims to address the significant unmet medical needs of patients suffering from various autoimmune diseases, leveraging its promising assets that have shown positive efficacy and safety data in cancer treatment.
Yihong Yao, Ph.D., Chief Scientific Officer of AbelZeta, stated, “With our CD20/BCMA and BCMA/CD19 bispecific CARs, we believe that these two assets will help address the significant unmet medical needs of many patients suffering from a variety of autoimmune diseases.”
The company’s approach involves advancing therapies tailored to individual patients, offering customized solutions for inflammatory and immunological diseases. The establishment of the SAB reinforces AbelZeta’s commitment to scientific excellence and the development of groundbreaking treatments in the field.
